Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $112.6 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 0.56% year-over-year to $112.6 million; the TTM value through Dec 2025 reached $404.8 million, down 3.88%, while the annual FY2025 figure was $112.6 million, 0.56% down from the prior year.
  • Liabilities and Shareholders Equity reached $112.6 million in Q4 2025 per LCTX's latest filing, up from $89.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $144.5 million in Q1 2022 and bottomed at $89.6 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $115.1 million, with a median of $112.6 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: grew 27.28% in 2021, then decreased 21.67% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $131.2 million in 2021, then decreased by 5.75% to $123.7 million in 2022, then decreased by 18.31% to $101.0 million in 2023, then grew by 12.08% to $113.2 million in 2024, then dropped by 0.56% to $112.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $112.6 million in Q4 2025, $89.6 million in Q3 2025, and $90.8 million in Q2 2025.